Resultats globals: 4 registres trobats en 0.01 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
13 p, 861.9 KB Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation : The phase III TOURMALINE-MM4 trial / Dimopoulos, M.A. (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens. School of Medicine) ; Špička, I. (First Department of Medicine. Department of Hematology. First Faculty of Medicine. Charles University. General Hospital in Prague) ; Quach, H. (Department of Hematology. University of Melbourne. St Vincent's Hospital) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hájek, R. (Department of Hemato-oncology. University Hospital Ostrava. University of Ostrava. Faculty of Medicine) ; Garg, M. (Hematology. Leicester Royal Infirmary. University Hospitals of Leicester NHS Trust) ; Beksac, M. (Department of Hematology. Ankara University) ; Bringhen, S. (Division of Hematology. University of Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino) ; Katodritou, E. (Department of Hematology. Theagenion Cancer Hospital) ; Chng, W.J. (Department of Hematology-Oncology. National University Cancer Institute. National University Health System. Yong Loo Lin School of Medicine. Cancer Science Institute of Singapore. National University of Singapore) ; Leleu, X. (Pôle Régional de Cancérologie. Department of Haematology. Centre Hospitalier Universitaire La Milétrie-Poitiers) ; Iida, S. (Department of Hematology and Oncology. Nagoya City University. Graduate School of Medical Sciences) ; Mateos, M.V. (Hematology. Hospital Universitario de Salamanca. University Hospital of Salamanca. Centro de Investigación del Cáncer. Instituto de Biología Molecular y Celular del Cáncer. Universitario de Salamanca Consejo Superior de Investigaciones Científicas) ; Morgan, G. (Perlmutter Cancer Center. NYU Langone Health) ; Vorog, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Labotka, R. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Wang, B. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Palumbo, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Lonial, S. (Department of Hematology and Medical Oncology. Winship Cancer Institute of Emory University) ; Universitat Autònoma de Barcelona
PURPOSE Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. [...]
2020 - 10.1200/JCO.20.02060
Journal of Clinical Oncology, Vol. 38 Núm. 34 (january 2020) , p. 4030-4041  
2.
11 p, 1.3 MB Melflufen for relapsed and refractory multiple myeloma / Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Larocca, A. (Azienda Ospedaliero-Universitaria Città Della Salute E Della Scienza Di Torino. University of Torino) ; Leleu, X. (Department of Hematology. CHU De Poitiers) ; Hajek, R. (Department of Hemato-Oncology. University of Ostrava and Faculty of Medicine. University of Ostrava) ; Hassoun, H. (Myeloma Service. Department of Medicine. Memorial Sloan Kettering Cancer Center) ; Rodríguez-Otero, P. (Department of Hematology. Clínica Universidad De Navarra) ; Paner, A. (Division of Hematology. Oncology and Stem Cell Transplant. Rush University Medical Center) ; Schjesvold, F.H. (Oslo Myeloma Center. Oslo University Hospital and K.G. Jebsen Centre for B-Cell Malignancies. University of Oslo) ; Gullbo, J. (Department of Medical Sciences. Division of Clinical Pharmacology. Uppsala University) ; Richardson, P.G. (Jerome Lipper Multiple Myeloma Center. Dana-Farber Cancer Institute. Harvard Medical School) ; Universitat Autònoma de Barcelona
Introduction: The overall survival of patients with multiple myeloma has improved with the advent of novel agents; however, multiple myeloma remains incurable. Combinations of standard-of-care agents such as immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies are increasingly used in earlier lines of therapy. [...]
2020 - 10.1080/13543784.2020.1808884
Expert Opinion on Investigational Drugs, Vol. 29 Núm. 10 (february 2020) , p. 1069-1078  
3.
8 p, 354.8 KB A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma / Hajek, R. (Faculty of Medicine. University of Ostrava) ; Pour, L. (University Hospital Brno) ; Ozcan, M. (Ankara University School of Medicine) ; Martin Sánchez, J. (Hospital Universitario Virgen del Rocio) ; García Sanz, R. (University Hospital of Salamanca) ; Anagnostopoulos, A. (General Hospital of Thessaloniki "G. Papanikolaou,") ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cascavilla, N. (IRCCS "Casa Sollievo della Sofferenza" Hospital) ; Terjung, A. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Lee, Y. (Pharmacyclics LLC. an AbbVie Company) ; Briso, E.M. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Dobkowska, E. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Hauns, B. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Špička, I. (1st Department of Medicine - Department of Hematology. First Faculty of Medicine. Charles University and General Hospital in Prague) ; Universitat Autònoma de Barcelona
Objective: We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies. [...]
2020 - 10.1111/ejh.13377
European Journal of Haematology, Vol. 104 Núm. 5 (january 2020) , p. 435-442  
4.
8 p, 788.7 KB A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) / Hájek, R. (University Hospital Ostrava) ; Masszi, T (St István and St László Hospital of Budapest) ; Petrucci,M.T. (Sapienza Università di Roma) ; Palumbo, A. (Università di Torino) ; Rosiñol, L. (Hospital Clínic i Provincial de Barcelona) ; Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ; Yong, K.L. (University College London Cancer Institute) ; Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Minarik, J. (University Hospital Olomouc and Medical Faculty of Palacky) ; Pour, L (University Hospital Ostrava) ; Dimopoulos, M.A. (National and Kapodistrian University of Athens) ; Maisnar, V. (Charles University Teaching Hospital, Hradec Králové) ; Rossi, D. (Amedeo Avogadro University of Eastern Piedmont) ; Kasparu, H. (Hospital Elisabethinen Linz) ; Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ; Yehuda, D.B. (Hadassah Medical Center, Jerusalem, Israel) ; Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ; Jenner, M. (Southampton General Hospital, Hampshire, UK) ; Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ; Dávid, M. (University of Pécs, Hungary) ; de la Rubia, J. (Hospital Universitario La Fe, València) ; Drach, J. (Medical University of Vienna) ; Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ; Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ; Leleu, X. (Hopital Huriez, CHRU, Lille, France) ; Munder, M. (University Medicine Mainz, Germany) ; Offidani, M (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ; Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ; Rajangam, K. (Onyx Pharmaceuticals, Inc.) ; Chang, Y.L. (Onyx Pharmaceuticals, Inc.) ; San-Miguel, J.F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Ludwig, H. (Wilhelminen Cancer Research Institute, Vienna, Austria)
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114  

Vegeu també: autors amb noms similars
4 Hajek, R.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.